Investor
ANDERA PARTNERS
CIK 0001757283 · filed 2026-02-17 · SEC filing
13F book
$176.6M
Positions
5
Largest name
38.1%
Kestra Med Technologies Ltd
Est. mark
—
Need a prior quarter to estimate
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| Kestra Med Technologies Ltd | — | 2.54M | $67.4M | 38.1% | — | Held |
| Mineralys Therapeutics, Inc. | MLYS | 1.59M | $57.8M | 32.7% | — | Held |
| Evommune, Inc. | EVMN | 1.9M | $32.5M | 18.4% | — | Held |
| Abivax Sa | — | 78.1K | $10.5M | 6.0% | — | Held |
| Inventiva Sa | — | 1.82M | $8.45M | 4.8% | — | Held |
Positions as of Q4 2025. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.